ArticleCancer cell international2026
PTX3 facilitates tumor cell migration and invasion through the miR-1255b-2-3p/CYP2J2 axis in oral squamous cell carcinoma.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral squamous cell carcinoma (OSCC) poses major clinical challenges because of its invasiveness and poor prognosis. Pentraxin 3 (PTX3) is an immune-modulating protein implicated in various types of cancer, although its role in OSCC remains unclear. In this study, we examined the functional roles and underlying molecular mechanisms of PTX3 in OSCC.
methodsThe effects of PTX3 on cell migration in human OSCC cells were investigated using a combination of RNA sequencing, transfection, Western blotting, quantitative RT-PCR, and Boyden chamber assays.
resultsBioinformatics and clinical data analyses revealed high PTX3 levels in OSCC tissues, associated with reduced patient survival. Functional assays revealed that PTX3 promotes migration and invasion in OSCC cells. Transcriptomic profiling identified cytochrome P450 family 2 subfamily J member 2 (CYP2J2) as a downstream target of PTX3. Mechanistically, PTX3 inhibits the expression of CYP2J2 by modulating the focal adhesion kinase/Src/extracellular signal-regulated kinase signaling pathway and upregulating miR-1255b-2-3p, which directly interacts with the 3'-untranslated region of CYP2J2.
conclusionsOverall, our findings elucidate a novel regulatory axis that involves PTX3, miR-1255b-2-3p, and CYP2J2 and drives the progression of OSCC, highlighting PTX3 as a potential therapeutic target and prognostic biomarker in OSCC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.